Chills

Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Retrieved on: 
Tuesday, March 26, 2024
COVID-19 vaccine, Risk, Headache, COVID-19, Ageing, Public, Vaccine, MRNA, Messenger, Chills, SARS-CoV-2, Myalgia, Clinical trial, Safety, Omicron, Fatigue

"We are excited to announce our fourth infectious disease vaccine program with positive Phase 3 data, further validating our robust mRNA platform," said Stephane Bancel, Chief Executive Officer of Moderna.

Key Points: 
  • "We are excited to announce our fourth infectious disease vaccine program with positive Phase 3 data, further validating our robust mRNA platform," said Stephane Bancel, Chief Executive Officer of Moderna.
  • "mRNA-1283 is a critical component of our combination vaccine against flu and COVID-19, mRNA-1083, and this milestone gives us confidence in our ability to bring this much needed vaccine to market."
  • In the NextCOVE (NCT05815498) Phase 3 pivotal trial, mRNA-1283 was shown to elicit a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2, compared to mRNA-1273.222.
  • A detailed analysis of the Phase 3 clinical trial data for mRNA-1283 will be shared at the Company's Vaccines Day event on March 27 and presented at upcoming scientific conferences.

ValleyScare is Back from the Dead!

Retrieved on: 
Tuesday, April 2, 2024
Halloween, Valleyfair, Policy, Sale, Moon, Chills, Amusement park

For those looking for a more family-friendly experience, Tricks and Treats is also returning with day-time Halloween fun this fall.

Key Points: 
  • For those looking for a more family-friendly experience, Tricks and Treats is also returning with day-time Halloween fun this fall.
  • Key features of ValleyScare include:
    ValleyScare will be operating select Fridays and Saturdays, September 21 through October 26, 2024.
  • In a change from previous years, ValleyScare will be a stand-alone event requiring a separate ticket.
  • We can’t wait for you to eagerly plunge into all the frighteningly fun, thrill-filled festivities.”
    For more information about ValleyScare, please visit valleyfair.com.

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Retrieved on: 
Tuesday, March 26, 2024
Connected, HIV-1, Amazon Prime Video, Breast milk, Face, Hypoesthesia, Patient, Chronic pain, Clostridioides, Heartburn, Lymph, Magnesium, Diarrhea, Myalgia, Spine, Allergy, Muscle weakness, Vonoprazan, Stomach, Vitamin, Dizziness, Potassium, Hip, Risk, Tongue, Chills, DTC, Safety, Food, PPI, Rash, Food and Drug Administration, GERD, Enzyme inhibitor, Skin, Esophagitis, HIV, Rilpivirine, Kidney, FDA, Esophagus, B-12, Weakness, Infection, Indigestion, Smart TV, Seizure, Inflammation, Polyp, Calcium, Extrapyramidal system, Bone fracture, Nausea, Spasm, Urine, Fever, Clostridioides difficile, Bleeding, Blood, Wrist, Blister, Vitamin B12, Human, Medicine, Pharmaceutical industry

FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announces the launch of its new broadcast ad and full-scale, Direct-to-Consumer (DTC) campaign, “VOQUEZNA Can Kick Some Acid,” to raise awareness of its powerful first-in-class treatment and encourage people to speak to their doctor about this new treatment option. VOQUEZNA (vonoprazan) is indicated for the healing and maintenance of healing of all severities of Erosive Esophagitis (EE), also referred to as Erosive GERD, and for the relief of related heartburn. VOQUEZNA represents the first major innovation to the U.S. Erosive GERD market in over 30 years.1

Key Points: 
  • The campaign will also be featured on consumer-facing platforms across Facebook, Instagram, waiting room TVs in doctor offices, and digital banner ads.
  • “Phathom is excited to launch our first campaign directly to, and for, the people whose lives we strive to improve every day.
  • To view a video of the “VOQUEZNA Can Kick Some Acid” commercial, click here.
  • Talk with your healthcare provider about the possibility of fundic gland polyps if you have been on VOQUEZNA for a long time.

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

Retrieved on: 
Tuesday, March 26, 2024
Diagnosis, Blood pressure, Efgartigimod alfa, System, Urination, Urinary tract infection, MHLW, Chest pain, Rituximab, Allergy, Disease, Infection, Risk, Headache, Patient, Sore throat, IWG, History, ITP, Chills, Quality of life, Cough, Euronext, Rash, Respiratory tract infection, Splenectomy, Medicine, Skin, Fever, Antibody, Wheeze, Back pain, Shivering, Safety, Pain, Fatigue, Phlegm, Swelling, Food, Autoimmune disease, Nursing

“argenx is on a mission to deliver transformative medicines for people living with severe autoimmune disease,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

Key Points: 
  • “argenx is on a mission to deliver transformative medicines for people living with severe autoimmune disease,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
  • By reducing circulating autoantibodies, VYVGART is uniquely designed to serve as a precision intervention that targets the underlying disease biology of ITP.
  • ADVANCE successfully met its primary endpoint, demonstrating that a higher proportion of chronic ITP patients receiving VYVGART achieved a sustained platelet count response compared to placebo.
  • Do not use VYVGART if you have a serious allergy to efgartigimod alfa or any of the other ingredients in VYVGART.

CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy

Retrieved on: 
Saturday, April 6, 2024
Guillain–Barré syndrome, Bone marrow, Medical College of Wisconsin, Encephalopathy, Survival, Immunotherapy, BCMA, Patient, Hypotension, Mortality, B-cell maturation antigen, Edema, Periodic breathing, Associate professor, Dexamethasone, Certification, Neutropenia, Dizziness, Risk, Headache, Chills, Myelodysplastic syndrome, Coagulopathy, DPD, Johnson & Johnson, Immune system, Effect, Fatigue, Thrombocytopenia, Food, Disease, Drive, Appetite, Lymphocytopenia, JNJ, Constipation, Multiple myeloma, Acute myeloid leukemia, CRS, Death, Hypersensitivity, Cytopenia, Cytokine release syndrome, ASCO, Use, Hematology, FDA, PVD, Annual general meeting, T cell, DSM-IV codes, Incidence, Tachycardia, Bortezomib, Diarrhea, Viral, Hope, United, Cough, Daratumumab, Nausea, Society, Division, Physician, Pharmaceutical industry

HORSHAM, Pa., April 5, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.1 With this approval, CARVYKTI® becomes the first and only B-cell maturation antigen (BCMA)-targeted therapy approved for the treatment of patients with multiple myeloma as early as first relapse.

Key Points: 
  • "This milestone underscores our commitment to improve outcomes for patients and transform the treatment of multiple myeloma with CARVYKTI," said Jordan Schecter, M.D., Vice President, Disease Area Leader, Multiple Myeloma, Johnson & Johnson Innovative Medicine.
  • CARVYKTI® is a cell therapy that works by harnessing a patient's immune system, or T cells, to fight the disease.
  • Treatment requires extensive training, preparation, and certification to ensure a positive experience for patients.
  • Since initial approval in February 2022, Johnson & Johnson has made significant advances in manufacturing to rapidly scale CARVYKTI® production.

Mouser Electronics Empowers Next Generation of Engineers by Sponsoring FIRST Robotics Competition for Youth

Retrieved on: 
Monday, April 1, 2024
Hardware, Semiconductor, Manufacturing, Other Education, Technology, Robotics, Finance, Primary, Secondary, Education, Professional Services, Children, Science, Consumer, Other Science, Engineering, Championship, Sport, BattleBots, Chills, FIRST Robotics Competition, Character, News, Senior, Marketing, NPI, Electronics, STEM, Robot, Multimedia, FIRST

Mouser will be a major sponsor at the upcoming FIRST® in Texas/UIL State Robotics Championships, occurring April 3-6 in the George R. Brown Convention Center in Houston, Texas.

Key Points: 
  • Mouser will be a major sponsor at the upcoming FIRST® in Texas/UIL State Robotics Championships, occurring April 3-6 in the George R. Brown Convention Center in Houston, Texas.
  • Additionally, Mouser will be the registration sponsor of the FIRST Championships, planned for April 17-20 at the same location.
  • Mouser supports FIRST teams in its local community, providing grants for high school teams across Tarrant County, Texas.
  • "As an avid supporter of the FIRST Robotics Competition since 2014, we are excited to be named this year's registration sponsor.

VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH

Retrieved on: 
Monday, April 1, 2024
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Factor D, Arthralgia, Chest pain, Confusion, Neuropsychological test, Infection, Eculizumab, Risk, Headache, ALPHA, PNH, C5, Patient, Orphan, Mitigation, Vaccine, Light, Paroxysmal nocturnal hemoglobinuria, EVH, Bacteria, University, Chills, MD, Breakthrough therapy, Cough, European Medicines Agency, Fatigue, Nausea, Rash, Fever, Priority, Safety, Immune system, REMS, Division, Vomiting, Hematology, Patient safety, Medicine

VOYDEYA has also been granted Orphan Drug Designation in the US, European Union (EU) and Japan for the treatment of PNH.

Key Points: 
  • VOYDEYA has also been granted Orphan Drug Designation in the US, European Union (EU) and Japan for the treatment of PNH.
  • You must complete or update meningococcal vaccine(s) and streptococcus vaccine(s) at least 2 weeks before your first dose of VOYDEYA.
  • If you have been vaccinated against these bacteria in the past, you might need additional vaccinations before starting VOYDEYA.
  • Carry it with you at all times during treatment and for 1 week after your last VOYDEYA dose.

CMUH (Taiwan) Launches "Intelligent Sepsis Early Prediction System (ISEPS)," Detecting Sepsis in One Minute Only

Retrieved on: 
Wednesday, April 3, 2024
Splenic infarction, Risk, Patient, Heart rate, Sepsis, Vomiting, Chills, Fungal infection, ECG, AI, Vital signs

TAICHUNG, Taiwan, April 3, 2024 /PRNewswire/ -- In conventional practice, a blood culture report wouldn't be available until 18 to 72 hours later, rendering it non-feasible to facilitate rapid response. Led by Superintendent Der-Yang Cho, CMUH's team developed "Intelligent Sepsis Early Prediction System (ISEPS)", the world's first AI-powered sepsis alarm system. The AI model of ISEPS takes only one minute for the early detection of sepsis and bacteremia to help clinicians identify patients at higher risk and provide early intervention with antibiotics to improve patient outcome and prevent it from progressing to sepsis. When compared to conventional blood cultures, it doesn't require additional blood collection or device operation, reducing the demands on healthcare labor while keeping the timeliness and quality of management.

Key Points: 
  • Led by Superintendent Der-Yang Cho, CMUH's team developed "Intelligent Sepsis Early Prediction System (ISEPS)", the world's first AI-powered sepsis alarm system.
  • The AI model of ISEPS takes only one minute for the early detection of sepsis and bacteremia to help clinicians identify patients at higher risk and provide early intervention with antibiotics to improve patient outcome and prevent it from progressing to sepsis.
  • Dr. Hong-Mo Shih, Deputy Director of CMUH Emergency Department, immediately activated cardiac catheterization team and ordered a routine complete blood count test.
  • With the ability to provide immediate bacteremia risk prediction, ISEPS provides the physicians timely and precisely assistance against infectious disease.

Clear Cut Hero Eclipse Is The Official Hydration Drink Of The 2024 Solar Eclipse

Retrieved on: 
Tuesday, April 2, 2024
Eclipse, Potassium, Thirst, Chills, Sodium, Electrolyte, Fructose, Solar eclipse, Safety, American Eclipse

LOUISVILLE, Ky., April 2, 2024 /PRNewswire/ -- Clear Cut Hero, the first-of-its-kind hydration drink, announced, to public fanfare, that its Eclipse flavor is the official hydration drink of the 2024 solar eclipse. Clear Cut Hero's Eclipse stands out as the perfect companion to keep enthusiasts refreshed and hydrated throughout this awe-inspiring event.

Key Points: 
  • Clear Cut Hero's Eclipse flavor will hydrate enthusiasts during the highly anticipated solar eclipse on April 8th, 2024
    LOUISVILLE, Ky., April 2, 2024 /PRNewswire/ -- Clear Cut Hero, the first-of-its-kind hydration drink, announced, to public fanfare, that its Eclipse flavor is the official hydration drink of the 2024 solar eclipse.
  • Joseph Nickell, CEO of Clear Cut Brands, parent of Clear Cut Hero, commented that 'Clear Cut Hero Eclipse is honored to contribute to the experience of this extraordinary celestial occurrence.
  • Clear Cut Hero Eclipse is a great addition to any 2024 Solar Eclipse viewing party.
  • Ryan McMillen, President of the Solar Eclipse Photography Club, commented 'Clear Cut Hero is the perfect source of hydration for those of us enduring the rigors of solar eclipse photography.

ATI PHYSICAL THERAPY RETURNS AS AN OFFICIAL PARTNER FOR THE 47TH ANNUAL McDONALD'S ALL AMERICAN HIGH SCHOOL BASKETBALL GAMES

Retrieved on: 
Wednesday, March 27, 2024
Health, ATI Physical Therapy, ESPN, Face, Sport, Therapy, Environment, Chills, Parent, Partnership, McDonald's, Travel, Boy, Athlete, ESPN2, Marketing, American Girl, Atmosphere, Injury, Sports medicine, Toyota Center, Toy

BOLINGBROOK, Ill., March 27, 2024 /PRNewswire/ -- ATI Physical Therapy, Inc., a nationally recognized outpatient physical therapy provider in the United States, is proud to announce its continued partnership as one of the official sponsors for the 47th Annual McDonald's All American Games, for the third consecutive year. The event, set to take place on April 2 at the Toyota Center in Houston, Texas, will showcase the nation's top high school basketball talent in a thrilling display of skill and high-level competition.

Key Points: 
  • Four dedicated ATI Sports Medicine athletic trainers will be on-site throughout the entirety of the event, providing 24/7 medical coverage.
  • "We are thrilled to be a part of the McDonald's All American High School Basketball Games for the third year in a row," said Rob Manker, Head of Marketing at ATI Physical Therapy.
  • ATI is also sponsoring the College Basketball Parents' Association's McDonald's All American Games Parent Celebration Brunch , with exclusive attendance by the players' parents.
  • ATI Physical Therapy looks forward to another year of excitement and excellence in high school basketball, supporting the athletes and their families every step of the way.